Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,187
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
A study understanding how much CDR132L enters the bloodstream after injection under the skin compared to injection into a vein in healthy participants
Novo Nordisk A/S
Healthy volunteers, treatment for heart failure
1 trial -
Investigating how CagriSema, semaglutide and cagrilintide regulate insulin effects in the body of people with type 2 diabetes.
Novo Nordisk A/S
Type 2 diabetes
1 trial -
Investigating how NNC0487-0111 regulates insulin in adults with type 2 diabetes
Novo Nordisk A/S
Type 2 Diabetes
1 trial -
Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Subcutaneous Injections of NNC0582-0001 in Healthy Adults
Novo Nordisk A/S
Healthy Volunteers
1 trial -
Investigation of pharmacokinetics, safety and tolerability of a single subcutaneous dose of NNC0487-0111 in participants with various degrees of renal impairment and normal renal function.
Novo Nordisk A/S
Obesity and Diabetes mellitus Typ 2
1 trial -
Methotrexate PK (in combination with Novobiocin) in RA patients
Pharma Mar S.A.
Rheumatoid arthritis
1 trial -
The Role of the Amylin Analogue Cagrilintide in Bone Metabolism
Novo Nordisk A/S
Female (aged between 50-70 years (both included)) with obesity (BMI ≥ 30.0 kg/m2) of post-menopausal state at screening (defined as minimum 12 months of amenorrhea and high levels of follicular stimulating hormone (FSH) ≥16 UI/L. In cases of uncertainty, confirmation of postmenopausal status requires low levels of anti-Müllerian hormone (AMH) and inhibin B).
1 trial -
To evaluate the pharmacokinetics and safety of nolasiban
Novo mesto
not applicable (submitted trial is a pharmacokinetic study in healthy subjects)
1 trial -
Understanding the effect of CagriSema, cagrilintide, and semaglutide on muscle health
Novo Nordisk A/S
Obesity, CCI, CCI
1 trial -
Lantus 100 units/ml solution for injection in a cartridge, Lantus 100 units/ml solution for injection in a vial, Toujeo 300 units/ml DoubleStar, solution for injection in a pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Levemir FlexPen 100 units/ml solution for injection in pre-filled pen., Toujeo 300 units/ml DoubleStar, solution for injection in a pre-filled pen, Tresiba 200 units/mL FlexTouch solution for injection in pre-filled pen, Tresiba 100 units/mL FlexTouch solution
Novo Nordisk A/S
Type 2 diabetes
1 trial -
Paracetamol Biofarm, 500 mg, tabletki, Placebo - Nalgesin forte, Nalgesin Forte, 550 mg, tabletki powlekane
Novo mesto
Knee osteoarthritis
1 trial -
Sorvasta 20 mg filmsko obložene tablete, Sorvitimb 20 mg/10 mg filmsko obložene tablete, Sorvasta 10 mg filmsko obložene tablete, Sorvasta 40 mg filmsko obložene tablete, Sorvitimb 40 mg/10 mg filmsko obložene tablete
Novo mesto
Hyperlipidaemia
1 trial -
Telmisartan/Amlodipine/Hydrochlorothiazide, Teldipin, 80 mg + 5 mg, tabletki, Telmisartan/Amlodipine/Hydrochlorothiazide, Tamloset 40 mg/5 mg tabletta, Tamloset 80 mg/10 mg tabletta, Telassmo 80 mg/10 mg tablete, Tamloset 80 mg/5 mg tabletta, Teldipin, 80 mg + 10 mg, tabletki, Telassmo 40 mg/5 mg tablete, Telmisartan/Amlodipine/Hydrochlorothiazide, Teldipin, 40 mg + 5 mg, tabletki, Telassmo 80 mg/5 mg tablete
Novo mesto
Arterial hypertension
1 trial -
Wegovy 0.25 mg FlexTouch solution for injection in pre-filled pen, Wegovy 1 mg FlexTouch solution for injection in pre-filled pen, Wegovy 0.5 mg FlexTouch solution for injection in pre-filled pen, Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen, Wegovy 1.7 mg FlexTouch solution for injection in pre-filled pen
Novo Nordisk A/S
Obesity
1 trial -
cagrilintide, Placebo + Placebo, semaglutide, cagrilintide, cagrilintide semaglutide, semaglutide, semaglutide, semaglutide, cagrilintide semaglutide, semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide, cagrilintide
Novo Nordisk A/S
Obesity and T2D
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources